Aethlon Medical (AEMD) Q3 2026 earnings review
Clinical Progress Funded by Massive Dilution
Aethlon is advancing its Australian oncology trial (Cohort 2) and exploring Long COVID applications, but shareholders are paying a steep price. While YTD operating expenses are down 27%, Q3 costs reversed trend, rising 14% to $2.06M as clinical activity ramped up. The company ended the quarter with $7.0M in cash—up from $5.5M in March—but this liquidity came from aggressive equity issuance, with the share count nearly quadrupling in nine months. Without revenue, Aethlon remains a high-risk clinical bet dependent on future safety data and continued financing.
🐂 Bull Case
The Hemopurifier oncology trial has advanced to Cohort 2 in Australia. The company also published data on Long COVID and demonstrated 98.5% removal of platelet-derived EVs in preclinical models, validating the platform's versatility.
Despite the Q3 uptick, management has successfully streamlined the business over the last nine months. YTD operating expenses dropped 27% to $5.36M, driven by lower professional fees and headcount reductions.
🐻 Bear Case
The share count exploded from ~259,000 in March 2025 to ~973,000 in December 2025. The cash runway is being extended solely through equity financing that significantly dilutes existing holders.
The trend of declining quarterly expenses broke this quarter. Q3 operating costs rose 13.6% YoY and 36% sequentially (vs Q2), indicating that clinical progress is becoming increasingly expensive.
⚖️ Verdict: 🔴
Bearish. While the clinical progress is real, the financial engineering required to sustain it is punishing. A 300%+ increase in share count in nine months and rising quarterly burn outweigh the long-term potential of early-stage safety trials.
Key Themes
Share Count Explosion
To maintain liquidity, Aethlon has aggressively tapped equity markets. Outstanding shares surged from 258,531 at the start of the fiscal year (March 31, 2025) to 973,213 by December 31, 2025. This 276% increase highlights the heavy cost of capital for pre-revenue biotech firms.
Operating Leverage Reversing
Reversing. For several quarters, the narrative was strict cost control. That changed in Q3. Payroll expenses jumped roughly $367,000 YoY, pushing total OpEx up 13.6% to $2.06M. While YTD costs are still lower, the quarterly trend indicates the 'lean' phase may be ending as trial costs mount.
Clinical Trial Momentum
The Australian oncology trial is actively enrolling Cohort 2. This follows the successful completion of Cohort 1. The study is critical for validating the Hemopurifier's safety profile in solid tumors, a prerequisite for any future efficacy studies or partnerships.
Platform Expansion: Long COVID
Aethlon is positioning the Hemopurifier as a 'pipeline within a device.' New data submitted for peer review shows the device binds EVs from Long COVID patients. While early-stage, this diversifies the potential addressable market beyond oncology.
Cash Burn vs. Balance
Cash stands at $7.0M. With the quarterly Net Loss rising to ~$2.0M (and likely to increase further with trial activity), the company has approximately 3-4 quarters of runway at current burn rates, implying the need for further capital raising soon.
Other KPIs
Stable/Improved vs March 2025 ($5.5M), but solely due to financing activities. Operations consumed ~$5.3M over the last nine months.
Decelerating. Down 26.9% from $7.34M in the prior year period. Savings driven by a $1.09M drop in payroll and $527k in G&A over the 9-month period, though Q3 showed a reversal of this trend.
Accelerating (worsening). Loss widened from $1.75M in the prior year quarter, driven by increased payroll and trial activity.
Guidance
Stable progress. Cohort 2 is actively enrolling. This study evaluates safety and dosing in solid tumor patients.
Progressing. Data published on bioRxiv and submitted for peer review. The company plans to investigate removal of platelet-derived EVs in plasma from patients with select indications.
Key Questions
Payroll Expense Spike
Payroll expenses increased nearly $370k YoY in Q3 despite the 9-month trend being down. Is this the new baseline for personnel costs as the trial ramps up?
India Trial Status
Previous updates mentioned a parallel trial in India. The current release focuses heavily on Australia. What is the status of the Indian regulatory approvals and site initiation?
Capital Strategy
With shares outstanding quadrupling in nine months and burn rate increasing, what is the strategy to fund operations beyond 2026 without further massive dilution?